Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-23
MYLAN
Dec-18
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,6843,945-   
Low Rs1,2312,171-   
Sales per share (Unadj.) Rs191.91,815.3-  
Earnings per share (Unadj.) Rs35.949.3-  
Cash flow per share (Unadj.) Rs39.8389.2-  
Dividends per share (Unadj.) Rs32.000-  
Avg Dividend yield %2.20-  
Book value per share (Unadj.) Rs102.91,963.8-  
Shares outstanding (eoy) m169.41514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x7.61.7 450.6%   
Avg P/E ratio x40.662.0 65.5%  
P/CF ratio (eoy) x36.77.9 466.5%  
Price / Book Value ratio x14.21.6 909.5%  
Dividend payout %89.20-   
Avg Mkt Cap Rs m246,8581,573,481 15.7%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m5,9500-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m32,517933,975 3.5%  
Other income Rs m1,0070-   
Total revenues Rs m33,524933,975 3.6%   
Gross profit Rs m8,033241,678 3.3%  
Depreciation Rs m658174,877 0.4%   
Interest Rs m1844,921 0.0%   
Profit before tax Rs m8,36421,880 38.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,288-3,481 -65.7%   
Profit after tax Rs m6,07625,361 24.0%  
Gross profit margin %24.725.9 95.5%  
Effective tax rate %27.4-15.9 -171.9%   
Net profit margin %18.72.7 688.2%  
BALANCE SHEET DATA
Current assets Rs m24,943521,531 4.8%   
Current liabilities Rs m13,264380,253 3.5%   
Net working cap to sales %35.915.1 237.4%  
Current ratio x1.91.4 137.1%  
Inventory Days Days9784 116.4%  
Debtors Days Days21693 231.4%  
Net fixed assets Rs m6,988181,176 3.9%   
Share capital Rs m1,694497 340.7%   
"Free" reserves Rs m15,7350-   
Net worth Rs m17,4301,010,390 1.7%   
Long term debt Rs m01,090,535 0.0%   
Total assets Rs m31,9302,710,259 1.2%  
Interest coverage x462.61.5 31,107.1%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.00.3 295.5%   
Return on assets %19.12.6 736.0%  
Return on equity %34.92.5 1,388.9%  
Return on capital %48.13.2 1,512.5%  
Exports to sales %00-   
Imports to sales %48.10-   
Net fx Rs m-14,0080-   
CASH FLOW
From Operations Rs m4,842194,080 2.5%  
From Investments Rs m8,079-100,318 -8.1%  
From Financial Activity Rs m-15,433-90,414 17.1%  
Net Cashflow Rs m-2,5121,608 -156.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare GSK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: AAREY DRUGS  VAISHALI PHARMA   SAKAR HEALTHCARE   AARTI DRUGS  CIAN HEALTHCARE  



Today's Market

Sensex Today Tanks 735 Points | IT & FMCG Stocks Drag | 5 Reasons Why Indian Share Market is Falling Sensex Today Tanks 735 Points | IT & FMCG Stocks Drag | 5 Reasons Why Indian Share Market is Falling(Closing)

After opening the negative note, Indian share markets continued the downtrend as the session progressed and ended the day weak.